Veradermics Prices the Pipeline Before Resale Supply Is Proven

Summary: Veradermics (MANE) is a conditional U.S. common-stock short Watchlist built around a fresh effective resale registration and proposed insider or investor sales, not a claim that VDPHL01 will fail. The August 14 Form 424B3 covers up to 16,772,058 common shares and 300,000 shares underlying pre-funded warrants. Against 41,780,136 common shares outstanding, the filing describes the resale block as approximately 40.6% of the outstanding common stock. Three Form 144 filings proposed sales totaling 421,749 shares at an aggregate market value of about $46.0 million, but a Form 144 is a notice of a proposed sale, not proof of completed resale. [1][3]

The counterargument is substantial. Veradermics held $819.9 million of cash, cash equivalents, and marketable securities at June 30, 2026, reported positive Phase 2/3 VDPHL01 data in males and positive Phase 2 data in females, and reported no product revenue because it remains clinical-stage. The latest Yahoo Finance reference is $109.12 at 2026-08-17T14:47:03Z, an intraday U.S. regular-session observation, not a closing price. At the filed denominator, that is an illustrative equity value of approximately $4.56 billion. entry.price is therefore null and execution.can_execute=false until borrow, liquidity, and a responsible entry are independently verified. [2][4]

This is research, not personalized financial advice. A resale registration and a Form 144 notice are not current float.

Scope and Research Audit

This run was explicitly limited to U.S. market short opportunities. I scanned articles/2026-08/week-3/ before selecting a topic, then cross-checked the repository by ticker, issuer, financing mechanism, resale registration, warrant stack, equity-line language, and prior direction.

The screen used unconventional filing combinations rather than a generic earnings query:

• selling stockholder resale registration Form 144 clinical-stage cash securities no product revenue
• pre-funded warrant registration effective proposed sale dermatology pipeline cash burn
• Nasdaq hearing panel offering pre-funded warrants cash runway clinical company
• at-the-market offering cash burn FDA-cleared device common denominator

The earlier BIVI screen in the August 8 article already covered the same best-efforts financing and potential-share mechanism, so it was not promoted to a new article despite the August 14 amendment. KITT, ICON, VEEA, Femasys, and other financing-led names were rejected as current-week duplicates or materially overlapping mechanisms. The active worktree is the current source of truth; the separate /Volumes/SSD/mispricing-desk checkout is stale and dirty and was not modified.

Opportunity Ranking

Rank	Idea	Fresh evidence	Why it could move more than 5%	Tradeability and rejection logic
1	Short MANE common	August 14 effective record and 424B3 resale prospectus; August 12 and 14 Form 144 notices	Up to 17.072M registered common-equivalent shares against 41.780M outstanding, plus proposed sales of 421,749 shares; the market is valuing a clinical-stage issuer at about $4.55B on the filed denominator	Selected. The dollar volume is materially better than the sub-$1 alternatives, but current spread, depth, borrow, and actual resale are unverified
2	Short DARE common	August 17 424B5 and 8-K; 4.086M common shares, 0.294M pre-funded warrants, and 8.759M common-warrant claims	The offering was priced at $1.37 against 15.170M common shares, while a late-August Nasdaq hearing adds a binary listing catalyst	Rejected for timing. The stock is already below $1 and near its 52-week low after a sharp repricing, so a new short would chase a thin, squeeze-prone tape
3	Short BEAT common	August 14 424B5 and August 13 10-Q; a $25M ATM with 42.387M illustrative shares at $0.5898	The ATM is roughly three-quarters of the 56.349M filed common denominator at the assumed price, while first-half operating cash use was $6.952M	Rejected. The financing is potential capacity, the stock already trades below the assumed price, and no equally urgent operating or regulatory catalyst was verified

Selected opportunity: conditional short MANE common stock.

Why this one now: The setup has four separate states that are easy to compress into one headline: an effective resale registration, proposed Form 144 sales, a large cash and securities balance, and a clinical pipeline with genuine positive data. The supply is not proven current float, but the registration and sale notices create an observable absorption test.

Why it can jump or dump more than 5% soon: A verified resale or a sequence of sales from the newly effective registration can challenge the price while the stock is still near its August range highs. The opposite path is also credible: strong VDPHL01 data, holder retention, or a positive regulatory update can squeeze a short in a stock that has traded between $32.00 and $131.24 over the last year. [4]

What should surprise a sophisticated reader: The registered block is about 40.6% of common stock, but the directly observed Form 144 notices total only about 1.0% of the filed denominator and do not prove that those shares were sold. The trade is about the transition from potential supply to completed resale, not about pretending that registration equals float.

The Setup

Veradermics is a clinical-stage biopharmaceutical company developing dermatology treatments. Its lead program, VDPHL01, is an extended-release oral formulation of minoxidil for pattern hair loss. The company reports no product revenue and has not obtained regulatory approval for a commercial product. [2]

The bull case is not cosmetic. The June 30 Form 10-Q reports that the male Study 302 Phase 2/3 trial met its primary and key secondary endpoints, with statistically significant hair-count and patient-reported outcomes. The filing also reports positive female Study 207 Phase 2 data. Management expects topline data from the female registration-directed Study 306 in the first half of 2027. Those facts create a real clinical counterweight to the resale thesis. [2]

The short question is narrower:

Is the current common stock priced as if clinical optionality will dominate the newly effective resale supply, even though a large block was acquired near the IPO or private-placement era and holders have now filed proposed sales?

The answer is not proven. That is why this is a Conditional Short Watchlist rather than an executable trade.

The Core Mispricing

Directly observed

The August 14 Form 424B3 registers up to 16,772,058 shares of common stock and 300,000 common shares issuable upon exercise of pre-funded warrants for selling stockholders. The pre-funded warrants have a $0.00001 exercise price. The company states that it will not receive proceeds from the resale of the common shares, except for cash exercise proceeds from the pre-funded warrants if any. The prospectus says the resale shares represent approximately 40.6% of total outstanding common stock as of August 6. [1]

The filing-based bridge is:

Bridge item	Value	State	Why it matters
Common shares outstanding at June 30	41,780,136	Filed common denominator	Base for all supply ratios
Registered common resale shares	16,772,058	Potential secondary supply	The company receives no resale proceeds
Registered pre-funded warrant shares	300,000	Potential common-equivalent supply	Nominal exercise price; exercise and resale remain separate events
Total registered common-equivalent shares	17,072,058	Potential supply	About 40.9% of June 30 common by simple arithmetic; the prospectus states approximately 40.6%
Illustrative value at $109.12	$1.86B	Stress arithmetic	Not a forecast of selling and not a price target
Form 144 proposed sales	421,749 shares	Proposed, not completed	About 1.0% of the filed common denominator
Form 144 aggregate market value	$45.96M	Proposed sale value	Indicates near-term seller intent, not completed public resale
Cash and marketable securities at June 30	$819.9M	Balance-sheet resource	Strong counterargument to a near-term funding crisis
Six-month operating cash flow	-$35.658M	Observed burn	The pipeline is expensive and remains pre-revenue
Six-month net loss	-$50.734M	Observed loss	Earnings are development-stage, not commercial

The distinction between the last two supply rows carries the thesis. Registration creates the ability to sell. Form 144 creates a proposed-sale notice. Neither proves that the shares have entered the public float. The cheapest short catalyst is an actual resale or a next share-count filing that shows the block moving from registered potential to observed supply.

The cash balance is the strongest counterargument

Veradermics had $319.333M of cash and $500.561M of current available-for-sale debt securities at June 30, for a total of $819.9M in cash, cash equivalents, and marketable securities. The same filing reports six-month operating cash use of $35.658M and says the existing resources should meet obligations for at least the twelve-month period from the date the financial statements became available. [2]

This is not a cash-distress short. The company raised capital through its IPO, a follow-on offering, and a May private placement. Its runway allows management to wait for clinical and regulatory milestones. That delay is a direct squeeze risk because a holder can retain registered shares while the company reports new positive data.

The pipeline is real, but it is not revenue

The company has reported positive male and female clinical results. It has not yet received regulatory approval or generated product sales. The 10-Q states that the company expects substantial future research, development, regulatory, and commercialization expenses, and that approval and market acceptance remain uncertain. [2]

Fact: VDPHL01 has positive disclosed clinical data.

Fact: The company remains pre-revenue and clinical-stage.

Inference: The market may be assigning a large value to successful commercialization while underweighting the timing and supply consequences of a newly effective resale registration.

Why the market may be right: The cash balance buys time, the pipeline has credible data, and actual proposed sales are small relative to the registered block.

Why the market may be wrong: A 40%-scale registered block and three proposed sales can make the price discovery process depend on supply absorption before the next clinical milestone arrives.

The Market Price

The latest available Yahoo Finance 5-minute chart snapshot showed MANE at $109.12 at 2026-08-17T14:47:03Z, during the U.S. regular session. The snapshot is intraday, not a close. The previous full daily bar closed at approximately $112.71 on August 14. The same chart reported an intraday range of approximately $107.68 to $111.28, current volume of about 104,055 shares, a 20-session average volume of approximately 798,850 shares, and a 52-week range of $32.00 to $131.24. [4]

Multiplying the filed 41,780,136 common shares by the $109.12 reference produces an illustrative equity value of approximately $4.56B. A provider market-cap field is not used as enterprise value because the quote and filing denominator are from different systems and dates, and the business has a large securities portfolio with no unified current debt and execution bridge in the same market snapshot. The article therefore uses price-only scenarios.

Market reference	Level	Timestamp / source	Interpretation
Current intraday reference	$109.12	2026-08-17T14:47:03Z, Yahoo Finance 5-minute chart	Context only, not an entry
Previous full daily close	$112.71	August 14, 2026, Yahoo Finance chart	Current reference is approximately 3.5% lower
Intraday range	$107.68-$111.28	August 17 5-minute chart snapshot	Current price is near the intraday lower end; do not short the low
Current reported volume	104,055 shares	Same chart snapshot	Incomplete session volume
20-session average volume	798,850 shares	Same chart series, prior 20 sessions	Liquidity context, not an expected fill estimate
52-week range	$32.00-$131.24	Same chart metadata	A positive clinical headline can create a large adverse move
Filing-based equity scale	$4.56B	41,780,136 x $109.12	Arithmetic reference, not enterprise value

The price is not at a clean technical entry. The current snapshot is near its intraday low, and no verified spread, depth, venue, or exit-liquidity data was available. The technical evidence is therefore a risk control only. The supply thesis survives if the chart is removed.

Positioning and Flow Evidence

The strongest current flow evidence is the sequence of Form 144 notices:

• AMZL, LP: proposed sale of 104,587 shares, aggregate market value $11.395M, approximate sale date August 12, acquired in a private placement.
• SR One Capital Fund II Aggregator, LP: proposed sale of 217,162 shares, aggregate market value $23.660M, approximate sale date August 12, acquired in a private placement.
• John W. Childs 2013 Revocable Trust: proposed sale of 100,000 shares, aggregate market value $10.905M, approximate sale date August 12, acquired in the IPO.

Together, the notices cover 421,749 shares and approximately $45.96M of stated market value. They are evidence of proposed supply and holder intent. They are not a transaction tape, and they do not prove that the full registered block will be sold. [3]

The direct positioning data that remains missing is more important than a stale short-interest headline:

• live locate and borrow availability;
• borrow rate, utilization, and recall terms;
• current short interest after the latest settlement date;
• full bid-ask spread and order-book depth;
• venue quality and exit liquidity;
• option open interest, implied volatility, and dealer positioning; and
• actual holder resale records after the Form 424B3 became effective.

The positioning score is 3/5. The registration and Form 144 notices are non-obvious flow evidence, but the absence of actual resale and borrow data blocks a higher score.

The Catalyst Path

The cheapest disconfirming sequence is a chain of observable events:

1. First regular-session tape after the effective registration. Replace the intraday reference with a fresh quote and verify spread, depth, venue, volume quality, and exit liquidity. The current reference is too close to the intraday low to support a responsible short entry.
2. First completed holder resale. Match any reported sale to the newly effective registration, Form 144 notice, seller, number of shares, and market impact. Do not count the prospectus as completed supply.
3. Next common-denominator and cash filing. Reconcile the 41.780M common base, any pre-funded warrant exercise, cash and securities, operating burn, and clinical spending. A stable denominator with improving clinical evidence weakens the short.
4. Next VDPHL01 clinical or regulatory update. The male Study 302 data and female Study 207 data are already positive. Study 306 topline data is expected in the first half of 2027, but no nearer dated event was verified in this run. A favorable update can overwhelm resale mechanics.
5. Actual commercialization or NDA path. The company's planned regulatory strategy and commercialization spending remain hypotheses until an NDA, approval, manufacturing plan, and sales bridge are filed. A registration does not settle that operating question.

The catalyst is partly mechanical and partly conditional. Resale creates supply only if holders sell. Clinical data can close the gap in the opposite direction. The short must be staged around evidence rather than the filing date alone.

The Gap

The market can be right for three reasons.

First, the cash balance is large. At June 30, cash and marketable securities were about $819.9M, and the first-half operating cash use was $35.7M. That resource gives Veradermics time to reach clinical milestones without immediately returning to the market. [2]

Second, the clinical data is better than a generic pre-revenue story. The male Phase 2/3 Study 302 met primary and key secondary endpoints, and the company reported positive female Phase 2 results. A clinical success can expand the value of the pipeline faster than a resale block can compress it. [2]

Third, the Form 144 notices are small relative to the total registration. Only about 1.0% of the filed common denominator is covered by the proposed-sale notices. The market may absorb that amount without a meaningful price response.

The differentiated disagreement is narrower:

The market may be treating the pipeline as the only relevant state, while the newly effective registration and proposed sales create a separate price-discovery event that can arrive before the next clinical proof point.

The edge is not a claim that 17.072M shares will be sold. It is the requirement that a short wait for actual resale evidence may be worth more than chasing a near-low price.

Payoff Map

The payoff is path-dependent. The top case requires completed resale, gradual absorption, and no new clinical surprise. The base case assumes the registration remains an overhang and the stock revisits a lower range without a full operational break. The bottom case is a clinical or regulatory squeeze, holder retention, or borrow recall that pushes the stock above its recent high.

Price Target and Probability Map

For a short, the Top Case is the favorable downside case and the Bottom Case is the adverse squeeze case. Gross short returns use the $109.12 reference price and exclude borrow, locate fees, slippage, halts, financing costs, taxes, and gap risk. The probabilities are analytical scenario weights, not forecasts.

Scenario	Probability	Target / level	Gross short payoff from $109.12	Time horizon	Conditions required	Evidence quality
Top Case for the short	30%	$72.00	+34.0% before costs	2 to 8 weeks	Actual resale begins, the registered block becomes a visible supply event, no positive clinical or regulatory surprise arrives, and liquidity remains sufficient to exit	Medium
Base Case	45%	$92.00	+15.7% before costs	2 to 8 weeks	The effective registration and proposed sales compress the multiple, but actual resale is gradual and the cash balance delays a larger break	Medium
Bottom Case for the short	25%	$145.00	-32.9% before costs	Days to 8 weeks	Holders retain the shares, VDPHL01 produces a favorable update, the next clinical milestone is accelerated, or borrow recall and thin liquidity force a squeeze	Medium to low
Invalidation / Stop Condition	n/a	Verified close above $145 without a new supply event, or failed borrow and liquidity gates	Thesis or execution invalidation	Immediate when observed	The clinical counterargument dominates, resale does not occur, or there is no responsible way to enter and exit	High for filing gates

Probability-weighted expected price: approximately $99.25, calculated as 30% x $72.00 + 45% x $92.00 + 25% x $145.00.

Price-only expected short payoff: approximately +9.0% from the $109.12 reference before borrow, fees, slippage, recalls, and transaction costs. Executable expected value is unknown because borrow and market-structure gates are unverified.

Current market price / level: $109.12, Yahoo Finance intraday reference.

Timestamp: 2026-08-17T14:47:03Z, U.S. regular session, not a close.

Primary instrument: MANE common stock.

Alternative expressions considered: Listed puts or put spreads were not used because a live option chain, open interest, implied volatility, bid-ask spread, and exit liquidity were not verified. A common-stock short is conceptually simpler but is not executable until locate, borrow, recall, spread, depth, venue, and exit conditions pass.

Confidence: Medium for the filing and balance-sheet bridge, low for execution and the timing of completed resale.

What Could Go Wrong

The strongest counterparty argument is that Veradermics has time and evidence. The company holds $819.9M of cash and marketable securities, has positive disclosed clinical data in male and female populations, and expects a female registration-directed data point in the first half of 2027. The company may be able to fund its pipeline long enough for clinical value to dominate any resale supply. [2]

The second counterargument is that registered shares are not current float. The Form 424B3 explicitly says the company does not know when or in what amount selling stockholders will dispose of their shares. The three Form 144 notices total only about 1.0% of common stock and are proposed sales, not completed trades. The market can absorb them.

The short can lose money even if resale supply eventually appears:

• a positive clinical or regulatory update arrives first;
• the holders retain shares while the pipeline re-rates;
• the company files a credible NDA, partner, or commercialization plan;
• the current intraday reference is stale or near a local low;
• borrow is recalled after a positive headline;
• a halt or gap jumps through the planned risk level; or
• the market pays a higher multiple for the cash-backed pipeline despite no completed resale.

What Would Prove This Wrong

Remove the short Watchlist or reprice it materially if any of the following occurs:

1. The next common-share and resale filings show no meaningful sale, the holders retain the registered block, and clinical or regulatory progress improves without a denominator increase.
2. The next filing confirms cash and marketable securities remain strong, operating burn is controlled, and the pipeline advances toward approval on a timeline that makes the resale overhang immaterial.
3. VDPHL01 produces a favorable clinical, regulatory, partnering, or commercialization update that supports a verified regular-session close above $145 without a new supply event.
4. The registration or holder restrictions prevent the near-term sales path assumed in the price map, or the proposed Form 144 sales are withdrawn and no other resale evidence appears.
5. Locate, borrow, recall, spread, depth, venue, or exit-liquidity gates fail. That blocks the trade expression even if the filing thesis remains interesting.

Best Trade Strategy

Control	Rule
Direction	Conditional short, only after actual resale evidence or a failed continuation with a fresh regular-session tape
Preferred instrument	MANE common stock, staged with limit orders only after locate, borrow, recall, spread, depth, venue, volume-quality, and exit-liquidity checks pass
Reference price	$109.12 at 2026-08-17T14:47:03Z, context only
Entry	Null. No executable entry is authorized by this research note
Take-profit map	Top $72.00, base $92.00, with $145.00 as the clinical and squeeze risk case
Invalidation	Verified close above $145 without a new supply event, no completed resale with improving clinical evidence, or a failed execution gate
Timeline	Next regular-session tape, first completed resale, next cash and denominator filing, and the Study 306 topline window in the first half of 2027
Do not trade	No locate, no borrow, adverse recall terms, wide spread, shallow depth, uncertain venue, price near an intraday low, halt, market order, leverage, margin, or unsupported options expression
Monitoring checklist	Form 144 completion or withdrawal, selling-stockholder resale, common denominator, pre-funded warrant exercise, cash and securities, operating burn, VDPHL01 enrollment, NDA timing, and clinical data

This is a Watchlist, not a trade instruction. The reference price is not an entry price. The market can absorb the proposed sales, and a clinical-stage issuer with $819.9M of cash and securities can wait longer than a short seller expects.

Bottom Line

MANE presents a real but conditional supply mismatch. The August 14 effective resale prospectus covers a common-equivalent block equal to roughly 40.6% of outstanding stock, while Form 144 notices proposed only 421,749 shares of sales. That gap is the point. The registration is potential supply, the notices are proposed supply, and actual resale remains unproven. The pipeline and cash balance make the counterargument strong enough to block a low-confidence short at the current intraday reference. The correct desk stance is a conditional short Watchlist, with entry.price=null and execution.can_execute=false until the market shows actual resale, acceptable borrow, and responsible liquidity.

Research Quality Scorecard

Criterion	Score	Evidence note
Market disagreement	5	A newly effective 40%-scale resale registration and proposed sales conflict with a cash-backed, clinically positive pipeline valuation
Evidence base	5	Fresh SEC 424B3, 10-Q, Form 144 XML, EFFECT record, companyfacts, and current Yahoo chart data support the bridge
Positioning and flows	3	Form 144 proposed sales and registration state are visible, but completed resale, borrow, short interest, options, and dealer flow are missing
Catalyst path	4	The effective registration, first resale, next denominator filing, and clinical milestones are observable, but timing is partly conditional
Payoff architecture	4	The price-only map is skewed lower, but cash, clinical data, holder retention, and squeeze risk leave a meaningful adverse tail
Invalidation discipline	5	Clinical, resale, cash, price, borrow, recall, and liquidity invalidators are explicit and monitorable
Differentiated insight	5	The key distinction is registration versus proposed sale versus completed resale, not a generic dilution count
Client value	4	The filing sequence and cash-versus-supply bridge remain useful even if borrow is unavailable or no short is taken

Total: 35 / 40.

This clears the publication threshold as a research note, but it remains a Conditional Short Watchlist because execution evidence and completed resale evidence are incomplete. The score measures underwriting quality, not the probability that a trade will make money.

Section 17 Quality Gate

#	Section 17 check	Answer	Evidence
1	Is the mispricing specific?	Yes	The article separates registration, proposed sales, completed resale, cash, and clinical value
2	Is there evidence beyond narrative?	Yes	Fresh SEC filings, Form 144 XML, companyfacts, and Yahoo chart data support the claims
3	Is positioning supported or clearly labeled uncertain?	Yes	Proposed sales are separated from actual resale; borrow and short-interest gaps are explicit
4	Is there a catalyst or closing mechanism?	Yes	Effective registration, first resale, next denominator filing, and clinical milestones are monitorable
5	Is downside described honestly?	Yes	$145 clinical and squeeze case, holder retention, gap risk, and borrow recall are explicit
6	Is the strongest counterargument included?	Yes	$819.9M of cash and securities and positive clinical data are lead counterarguments
7	Is the article useful without a trade?	Yes	The registration-to-resale and cash-to-clinical monitoring sequence remains useful
8	Are factual claims sourced or marked uncertain?	Yes	Material claims link to SEC or Yahoo sources; stress calculations are labeled
9	Does the article avoid hype?	Yes	No hype, certainty, or personalized advice language
10	Does the headline match the evidence?	Yes	It describes pipeline valuation before resale proof, not an insolvency claim
11	Does it explain why this is best now?	Yes	MANE wins on fresh effectiveness, proposed sales, dollar liquidity, and a distinct current-week setup
12	Is a greater-than-5% near-term move plausible?	Yes	Completed resale can pressure the stock; clinical data or holder retention can squeeze it within the stated windows
13	Is the sophisticated-reader surprise identified?	Yes	The registered block is large, but directly proposed sales are only about 1% and are not completed resale
14	Do top, base, and bottom probabilities total 100%?	Yes	30% + 45% + 25% = 100%
15	Is the scorecard in the main file?	Yes	Dedicated Research Quality Scorecard section included
16	Are all reader-facing tables Markdown?	Yes	Ranking, bridge, market data, payoff, strategy, scorecard, and sources are Markdown
17	Were optional table images handled correctly?	Yes, not requested	No table-image artifact was requested or created
18	Is the required illustration prompt inline with watermark language?	Yes	Inline prompt includes a subtle The Mispricing Desk watermark requirement
19	Is Best Trade Strategy complete?	Yes	Direction, instrument, null entry, targets, invalidation, timeline, execution gates, and monitoring are included
20	Are technical signals only timing inputs?	Yes	Price and volume are execution context only; the thesis survives without technical indicators
21	Were all four geographies screened?	Yes, user scope override	The user explicitly limited this run to U.S. market short opportunities
22	Was Japan small-cap and <= JPY 800 preference applied?	Yes, not applicable	Japan was excluded under the explicit U.S.-only instruction
23	Was live Substack finish completed?	Yes, not requested	The request required local article, signal, process updates, commit, and push, not a Substack post
24	Is the synchronized signal, build, generated output, and diff check complete?	Yes	The extended MANE signal matches the generated output; npm run build and git diff --check pass

Sources

#	Source	What it supports
1	Veradermics August 14, 2026 Form 424B3 resale prospectus and SEC effectiveness record	Registered 16,772,058 common shares, 300,000 pre-funded warrant shares, 40.6% filing description, seller terms, and no issuer resale proceeds
2	Veradermics June 30, 2026 Form 10-Q	Cash, marketable securities, common denominator, operating burn, net loss, pre-revenue status, VDPHL01 data, and Study 306 timing
3	AMZL Form 144, SR One Form 144, and John W. Childs Trust Form 144/A	Proposed sale quantities, market values, approximate sale date, and acquisition source
4	MANE Yahoo Finance 5-minute chart and 3-month daily chart	August 17 intraday reference, prior full close, range, volume, 20-session volume context, and 52-week range
5	Daré Bioscience August 17, 2026 Form 424B5, June 30, 2026 Form 10-Q, and DARE Yahoo Finance chart	Ranked alternative: financing terms, cash, burn, Nasdaq hearing, and price reset
6	HeartBeam August 14, 2026 Form 424B5, June 30, 2026 Form 10-Q, and BEAT Yahoo Finance chart	Ranked alternative: ATM capacity, illustrative shares, cash, burn, and price reset
7	BIVI August 14, 2026 Form S-1/A and August 8, 2026 prior article	Duplicate-screen reason for excluding a previously screened, same-mechanism candidate

AI Illustration Prompt

Create a realistic, high-value, high-end elite, beautiful master editorial illustration for The Mispricing Desk about Veradermics (MANE): a clinical-stage dermatology company whose cash-backed pipeline is being weighed against a newly effective resale registration. Use a restrained institutional composition on warm paper. On the left, show a precise glass laboratory vial and a clinical-trial dossier labelled "VDPHL01", "positive Study 302", "Study 306 topline H1 2027", and "no product revenue". On the right, build a clean capital-structure ledger with a thin rust-red supply line labelled "16.772M registered common shares", "0.300M pre-funded shares", "40.6% of common", and "421,749 proposed Form 144 shares". Place a deep cash reserve tile beneath the laboratory reading "cash + marketable securities $819.9M" and a smaller burn tile reading "H1 operating cash flow -$35.7M". Include a balance scale between clinical optionality and resale supply, with no implication that registration equals completed sale. Add a restrained price marker "MANE $109.12, Aug 17 intraday" and a small warning tile "reference only, borrow and depth unverified". Use paper white, graphite, deep navy, slate blue, muted clinical green, muted rust, and one controlled red execution accent. The mood is analytical, sober, and unresolved. Avoid rockets, casino imagery, candlestick-chart wallpaper, cartoon money, generic stock-photo language, or promotional AI clichés. Include a subtle but clear watermark/text reading "The Mispricing Desk" in the lower-right corner.